Malignant Mesothelioma of the Tunica Vaginalis Testis: Outcomes Following Surgical Management Beyond Radical Orchiectomy


      To describe clinical management and outcomes of a cohort of patients with malignant mesothelioma of the tunica vaginalis testis (MMTVT) who received treatments beyond radical orchiectomy.


      Patients with confirmed MMTVT at a single tertiary care institution were identified. Treatments, pathologic outcomes, and survival were recorded. Prognostic variables associated with survival were analyzed with a Cox proportional hazards model and Kaplan-Meier curves.


      Overall, 15 patients were included. Initial presentation was a scrotal mass in 7 of 15 (47%) and hydrocele in 5 of 15 (33%) patients. Clinical staging revealed enlarged nodes in 5 of 15 (33%) patients. Radical orchiectomy was the initial treatment in 5 of 15 (33%) patients. Positive surgical margins were found in 6 of 14 (43%) radical orchiectomies and were associated with worse survival (P = .007). The most frequent histologic subtype was epithelioid, associated with better survival (P = .048). Additional surgeries were performed on 12 of 15 (80%) patients. Pathologic examination revealed MMTVT in 6 of 12 (50%) hemiscrotectomies, 7 of 8 (88%) retroperitoneal lymph node dissections, 1 of 7 (14%) pelvic lymph node dissections, and 10 of 10 (100%) groin dissections. Five patients received adjuvant chemotherapy. Two also received adjuvant radiation therapy. Three patients with lymph node involvement remain no evidence of disease over 6 years after diagnosis. After a median follow-up of 3.5 years (interquartile range: 1.2-7.2), 5 patients have died, all of MMTVT; the median overall survival has not been reached. Common sites of relapse were lungs (5 of 7) and groin (3 of 7).


      The pattern of metastatic spread of MMTVT is predominantly lymphatic. Nodes in the retroperitoneum and the groin are commonly involved. Prognosis is poor, but there may be a role for aggressive surgical resection including hemiscrotectomy, and inguinal and retroperitoneal lymph nodes.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Chekol S.S.
        • Sun C.C.
        Malignant mesothelioma of the tunica vaginalis testis: diagnostic studies and differential diagnosis.
        Arch Pathol Lab Med. 2012; 136: 113-117
        • Barbera V.
        • Rubino M.
        Papillary mesothelioma of the tunica vaginalis.
        Cancer. 1957; 10: 183-189
        • Bertolotto M.
        • Boulay-Coletta I.
        • Butini R.
        • et al.
        Imaging of mesothelioma of tunica vaginalis testis.
        Eur Radiol. 2016; 26: 631-638
        • Hai B.
        • Yang Y.
        • Yao Y.
        • et al.
        Diagnosis and prognosis of malignant mesothelioma of the tunica vaginalis testis.
        Can Urol Assoc J. 2012; 6: E238-E241
        • Plas E.
        • Riedl C.R.
        • Pflüger H.
        Malignant mesothelioma of the tunica vaginalis testis: review of the literature and assessment of prognostic parameters.
        Cancer. 1998; 83: 2437-2446
        • Mensi C.
        • Pellegatta M.
        • Sieno C.
        • et al.
        Mesothelioma of tunica vaginalis testis and asbestos exposure.
        BJU Int. 2012; 110: 533-537
        • Kao S.C.
        • Reid G.
        • Lee K.
        • et al.
        Malignant mesothelioma.
        Intern Med J. 2010; 40: 742-750
        • Bueno R.
        • Stawiski E.W.
        • Goldstein L.D.
        • et al.
        Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations.
        Nat Genet. 2016; 48: 407-416
        • Magge D.
        • Zenati M.S.
        • Austin F.
        • et al.
        Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis.
        Ann Surg Oncol. 2014; 21: 1159-1165
        • Vogelzang N.J.
        • Rusthoven J.J.
        • Symanowski J.
        • et al.
        Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
        J Clin Oncol. 2003; 21: 2636-2644